TiGenix obtains commercial production license for expanded manufacturing facility

by TIGENIX SAU

7 years ago
stem cell therapy, Cx601, commercial roll out, AEMPS

Provides capacity for potential European commercial roll out of investigational stem cell therapy, Cx601. Expanded facility also secures manufacturing for other pipeline products

Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients

by TIGENIX SAU

7 years ago
Swissmedic, Crohn’s disease, Cx601, perianal fistulas

Takeda Pharma AG (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced that the Swiss Agency for Therapeutic Products (Swi...

TiGenix Cx601 positive long-term results to be presented at digestive disease week

by TIGENIX SAU

7 years ago
Cx601, clinical trial, perianal fistulas, Crohn’s disease

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop nove...

TiGenix provides update on Cx601 marketing authorization application procedure in Europe

by TIGENIX SAU

7 years ago
allogeneic stem cells, Cx601, LoOI, Marketing Authorization

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cell...

TiGenix announces Orphan Drug Designation (ODD) for Cx601 in Switzerland

by TIGENIX SAU

8 years ago
Cx601, Crohn’s disease, Orphan Drug Designation

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells...

Takeda and TiGenix Announce the Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease

by TIGENIX SAU

8 years ago
Cx601, TiGenix, Takeda, Crohn’s Disease, ADMIRE-CD Trial, Perianal Fistulas

Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Dis...

Takeda and TiGenix enter into licensing agreement for Ex-U.S. rights to Cx601 for the treatment of complex perianal fistulas in patients with crohn’s disease

by TIGENIX SAU

8 years ago
Cx601, perianal fistulas, Crohn’s disease, eASC

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels: TIG) (“TiGenix”) today announced that the companies have entered into an exclusive ex-U.S. li...

USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas

by TIGENIX SAU

9 years ago
TiGenix, Cx601

The patent, entitled “Use of adipose tissue-derived stromal stem cells in treating fistula”, expires in 2030 and provides coverage for the company’s lead development product, Cx601, in the key U...